Clinical characteristics of osteosarcoma patients (<i>N</i> = 102).

<p>Clinical characteristics of osteosarcoma patients (<i>N</i> = 102).</p

Kaplan-Meier survival curves for osteosarcoma patients according to genotype for (A) rs4148416 in <i>ABCC3</i> (X² = 21.4, <i>p-value</i> = 3.8×10⁻⁶); (B) rs4148737 in <i>ABCB1</i> (X² = 18.4, <i>p-value</i> = 1.0×10⁻⁴); and (C) rs1128503 or rs10276036 in <i>ABCB1</i> (X² = 20.9, <i>p-value</i> = 2.9×10⁻⁵<i>).</i>

<p>Kaplan-Meier survival curves for osteosarcoma patients according to genotype for (A) rs4148416 in <i>ABCC3</i> (X² = 21.4, <i>p-value</i> = 3.8×10⁻⁶); (B) rs4148737 in <i>ABCB1</i> (X² = 18.4, <i>p-value</i> = 1.0×10⁻⁴); and (C) rs1128503 or rs10276036 in <i>ABCB1</i> (X² = 20.9, <i>p-value</i> = 2.9×10⁻⁵<i>).</i></p

Genes and polymorphisms associated with overall survival (OS) and event free survival (EFS).

<p>*HR: Hazard Ratio.</p><p>**Analysis adjusted for metastasis at diagnosis.</p

Genomewide high-density SNP linkage analysis of non-BRCA1/2 breast cancer families identifies various candidate regions and has greater power than microsatellite studies-1

<p><b>Copyright information:</b></p><p>Taken from "Genomewide high-density SNP linkage analysis of non-BRCA1/2 breast cancer families identifies various candidate regions and has greater power than microsatellite studies"</p><p>http://www.biomedcentral.com/1471-2164/8/299</p><p>BMC Genomics 2007;8():299-299.</p><p>Published online 30 Aug 2007</p><p>PMCID:PMC2072960.</p><p></p>rker loci (r> 0.2/0.5/0.8), and B) marker densities (0.5 cM/1 cM/2 cM)

Supplementary Figure S3 from Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancer–Predisposing Mutations in Pheochromocytomas and Paragangliomas

(A) Aspartate/glutamate ratios assessed by LC-MS in GOT2 KD Hela cells transfected with empty vector (EV), GOT2 wild-type (WT) cDNA, GOT2- c.223T>G cDNA, and GOT2- c.357A>T cDNA. The ratios were reported as means (n=3). Error bars represent standard deviations. A t-test was applied to test for differences between GOT WT and GOT2- c.223T>G and - c.357A>T transfected cells. n.s.: not significant. (B) Succinate/fumarate ratios assessed by LC-MS in OGDHL KD Hela cells transfected with EV, OGDHL WT cDNA, and OGDHL- c.750G>T cDNA. The ratios were reported as means (n=3). Error bars represent standard deviations. A t-test was applied to test for differences. n.s.: not significant</p

Genomewide high-density SNP linkage analysis of non-BRCA1/2 breast cancer families identifies various candidate regions and has greater power than microsatellite studies-3

<p><b>Copyright information:</b></p><p>Taken from "Genomewide high-density SNP linkage analysis of non-BRCA1/2 breast cancer families identifies various candidate regions and has greater power than microsatellite studies"</p><p>http://www.biomedcentral.com/1471-2164/8/299</p><p>BMC Genomics 2007;8():299-299.</p><p>Published online 30 Aug 2007</p><p>PMCID:PMC2072960.</p><p></p

Genomewide high-density SNP linkage analysis of non-BRCA1/2 breast cancer families identifies various candidate regions and has greater power than microsatellite studies-0

<p><b>Copyright information:</b></p><p>Taken from "Genomewide high-density SNP linkage analysis of non-BRCA1/2 breast cancer families identifies various candidate regions and has greater power than microsatellite studies"</p><p>http://www.biomedcentral.com/1471-2164/8/299</p><p>BMC Genomics 2007;8():299-299.</p><p>Published online 30 Aug 2007</p><p>PMCID:PMC2072960.</p><p></p

Genomewide high-density SNP linkage analysis of non-BRCA1/2 breast cancer families identifies various candidate regions and has greater power than microsatellite studies-2

<p><b>Copyright information:</b></p><p>Taken from "Genomewide high-density SNP linkage analysis of non-BRCA1/2 breast cancer families identifies various candidate regions and has greater power than microsatellite studies"</p><p>http://www.biomedcentral.com/1471-2164/8/299</p><p>BMC Genomics 2007;8():299-299.</p><p>Published online 30 Aug 2007</p><p>PMCID:PMC2072960.</p><p></p> bottom of each panel

Supplementary Figure S1 from Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancer–Predisposing Mutations in Pheochromocytomas and Paragangliomas

(A) Quantitative PCR analysis of RBP1 expression of the 49 tumors included in the study compared to controls comprising five tumors carrying mutation in Krebs cycle genes and five cases carrying mutations in RET or NF1. RU: relative units. (B) SDHB immunohistochemistry of tumor_4 compared to a positive control tumor carrying a non-SDH mutation. The scale bars represent 50μm. (C) Representation of DNA methylation (M_values) of the CpG island probes located within the SDHC locus of tumor_4 compared to a blood sample from the same patient and a control DNA. (D) Immunohistochemical staining of 5-hmC in IDH3B-mutated tumor. Nuclear 5-hmC was observed only in sustentacular and some stromal cells. The scale bar represents 50μm.</p

Supplementary Figure Legends from Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancer–Predisposing Mutations in Pheochromocytomas and Paragangliomas

Legends of the Supplementary Figures</p